{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:57Z","timestamp":1792123677751,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific & Industrial Research","doi-asserted-by":"publisher","award":["MLP-2035"],"award-info":[{"award-number":["MLP-2035"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bcp.2024.116587","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T18:08:29Z","timestamp":1729620509000},"page":"116587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"P2","title":["Therapeutic targeting of Wnt antagonists by small molecules for treatment of osteoporosis"],"prefix":"10.1016","volume":"230","author":[{"given":"Aarti","family":"Abhishek Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwan","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakir","family":"Ahamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konica","family":"Porwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Chourasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor","family":"Mohanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinshuk R.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naibedya","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116587_b0005","doi-asserted-by":"crossref","unstructured":"A.E. Litwie, A. Debska-\u015alizie\u0144, E. Dennison, Secondary osteoporosis, in: Osteoporosis Treatment: A Clinical Overview, Springer International Publishing, Cham, 2021: pp. 177\u2013200. https:\/\/doi.org\/10.1007\/978-3-030-78128-6_11.","DOI":"10.1007\/978-3-030-78128-6_11"},{"key":"10.1016\/j.bcp.2024.116587_b0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrendo.2011.146","article-title":"Antiresorptive therapies for osteoporosis: a clinical overview","volume":"8","author":"Chen","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2024.116587_b0015","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/13543784.2010.501077","article-title":"Investigational anabolic therapies for osteoporosis","volume":"19","author":"Trivedi","year":"2010","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bcp.2024.116587_b0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcp.2019.05.024","article-title":"Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide","volume":"166","author":"Bhattacharyya","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116587_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20010083","article-title":"Anabolic therapies in osteoporosis and bone regeneration","volume":"20","author":"Russow","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116587_b0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14656566.2018.1428559","article-title":"New and developing pharmacotherapy for osteoporosis in men","volume":"19","author":"Gennari","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116587_b0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2018.02.028","article-title":"Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action","volume":"826","author":"Bhattacharyya","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116587_b0040","doi-asserted-by":"crossref","first-page":"43399","DOI":"10.1038\/srep43399","article-title":"Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties","volume":"7","author":"Ma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116587_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2024.116587_b0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures","volume":"16","author":"Starr","year":"2018","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bcp.2024.116587_b0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2024.116587_b0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/STROKEAHA.108.518621","article-title":"Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease","volume":"40","author":"Mosca","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.bcp.2024.116587_b0065","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1177\/1060028013509233","article-title":"Salmon calcitonin use and associated cancer risk","volume":"47","author":"Overman","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116587_b0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-015-3339-z","article-title":"Does salmon calcitonin cause cancer?","volume":"27","author":"Wells","year":"2016","journal-title":"A Review and Meta-Analysis, Osteoporosis International."},{"key":"10.1016\/j.bcp.2024.116587_b0075","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcp.2024.116587_b0080","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrm3470","article-title":"The complex world of WNT receptor signalling","volume":"13","author":"Niehrs","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2024.116587_b0085","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1074\/jbc.M114.561209","article-title":"Identification of Key Residues and Regions Important for Porcupine-mediated Wnt Acylation","volume":"289","author":"Rios-Esteves","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116587_b0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2024.116587_b0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gendis.2023.01.030","article-title":"Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk","volume":"11","author":"Qin","year":"2024","journal-title":"Genes & Diseases."},{"key":"10.1016\/j.bcp.2024.116587_b0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the WNT pathway?","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2024.116587_b0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.2653","article-title":"Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis","volume":"18","author":"Maeda","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2024.116587_b0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbrc.2011.11.089","article-title":"Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir","volume":"417","author":"Santiago","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2024.116587_b0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jbmr.2599","article-title":"Wnt signaling inhibits osteoclast differentiation by activating canonical and noncanonical cAMP\/PKA pathways","volume":"31","author":"Weivoda","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.bcp.2024.116587_b0120","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/cdd.2014.238","article-title":"CXXC5 is a negative-feedback regulator of the Wnt\/\u03b2-catenin pathway involved in osteoblast differentiation","volume":"22","author":"Kim","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2024.116587_b0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4248\/BR201301004","article-title":"A comprehensive overview of skeletal phenotypes associated with alterations in Wnt\/\u03b2-catenin signaling in humans and mice","volume":"1","author":"Maupin","year":"2013","journal-title":"Bone Res."},{"key":"10.1016\/j.bcp.2024.116587_b0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00019605-199704000-00011","article-title":"Persistent hyperplastic primary vitreous in a family with osteoporosis-pseudoglioma syndrome","volume":"6","author":"Steichen-Gersdorf","year":"1997","journal-title":"Clin. Dysmorphol."},{"key":"10.1016\/j.bcp.2024.116587_b0135","first-page":"146","article-title":"Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13","volume":"59","author":"Gong","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0140","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ejmg.2017.09.001","article-title":"High bone mass due to novel LRP5 and AMER1 mutations","volume":"60","author":"Costantini","year":"2017","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bone.2017.12.002","article-title":"Novel familial mutation of LRP5 causing high bone mass: Genetic analysis, clinical presentation, and characterization of bone matrix mineralization","volume":"107","author":"Roetzer","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2024.116587_b0150","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1359\/JBMR.050303","article-title":"An autosomal dominant high bone mass phenotype in association with craniosynostosis in an extended family is caused by an LRP5 missense mutation","volume":"20","author":"Kwee","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.bcp.2024.116587_b0155","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1086\/368277","article-title":"Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density","volume":"72","author":"Van Wesenbeeck","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0160","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/jmg.25.3.200","article-title":"Sclerosteosis","volume":"25","author":"Beighton","year":"1988","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0165","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/302416","article-title":"Localization of the gene for sclerosteosis to the van buchem disease-gene region on chromosome 17q12\u2013q21","volume":"64","author":"Balemans","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0170","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot-Containing Protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0180","doi-asserted-by":"crossref","first-page":"E1526","DOI":"10.1002\/humu.21274","article-title":"First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function","volume":"31","author":"Piters","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bcp.2024.116587_b0185","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bone.2012.10.009","article-title":"Novel SOST gene mutation in a sclerosteosis patient and her parents","volume":"52","author":"Bhadada","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2024.116587_b0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00439-011-0947-3","article-title":"Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia","volume":"129","author":"Kim","year":"2011","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0200","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","author":"Staehling-Hampton","year":"2002","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.bcp.2024.116587_b0205","first-page":"1","author":"Corso","year":"2022","journal-title":"DiffDock: Diffusion Steps, Twists, and Turns for Molecular Docking"},{"key":"10.1016\/j.bcp.2024.116587_b0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.celrep.2016.12.017","article-title":"Conformational Freedom of the LRP6 Ectodomain Is Regulated by N-glycosylation and the Binding of the Wnt Antagonist Dkk1","volume":"18","author":"Matoba","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2024.116587_b0215","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/nsmb.2139","article-title":"Crystal structures of the extracellular domain of LRP6 and its complex with DKK1","volume":"18","author":"Cheng","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2024.116587_b0220","doi-asserted-by":"crossref","first-page":"e11014","DOI":"10.1371\/journal.pone.0011014","article-title":"Dkk1 Stabilizes Wnt Co-Receptor LRP6: implication for Wnt Ligand-Induced LRP6 Down-Regulation","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116587_b0225","first-page":"1","article-title":"Drug Discovery of DKK1 Inhibitors","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116587_b0230","unstructured":"M.P. Yavropoulou, J.G. Yovos, Osteoclastogenesis\u2013current knowledge and future perspectives, Journal of Musculoskeletal & Neuronal Interactions 8 (2008) 204\u2013216. PMID: 18799853."},{"key":"10.1016\/j.bcp.2024.116587_b0235","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/jcmm.14046","article-title":"CXXC5: A novel regulator and coordinator of TGF-\u03b2, BMP and Wnt signaling","volume":"23","author":"Xiong","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2024.116587_b0240","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10822-018-0118-x","article-title":"Discovery of a small-molecule inhibitor of Dvl\u2013CXXC5 interaction by computational approaches","volume":"32","author":"Ma","year":"2018","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bcp.2024.116587_b0245","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bmcl.2018.01.050","article-title":"In silico discovery of quinoxaline derivatives as novel LRP5\/6-sclerostin interaction inhibitors","volume":"28","author":"Choi","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2024.116587_b0250","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/ajhp\/zxaa285","article-title":"Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis","volume":"77","author":"Prather","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.bcp.2024.116587_b0255","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1186\/s12967-023-04563-z","article-title":"Romosozumab in osteoporosis: yesterday, today and tomorrow","volume":"21","author":"Wu","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2024.116587_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.63402","article-title":"Sclerostin small-molecule inhibitors promote osteogenesis by activating canonical Wnt and BMP pathways","volume":"12","author":"Sangadala","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2024.116587_b0265","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bone.2018.05.011","article-title":"The anti-epileptic drugs valproate, carbamazepine and levetiracetam cause bone loss and modulate Wnt inhibitors in normal and ovariectomised rats","volume":"113","author":"Parveen","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2024.116587_b0270","doi-asserted-by":"crossref","first-page":"871","DOI":"10.33549\/physiolres.933267","article-title":"Identification of novel small molecules that bind to the Loop2 region of sclerostin - an in silico computational analysis","volume":"65","author":"Muthusamy","year":"2016","journal-title":"Physiol. Res."},{"key":"10.1016\/j.bcp.2024.116587_b0275","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1080\/07391102.2019.1599427","article-title":"Discovery of potential sclerostin inhibitors from plants with loop2 region of sclerostin inhibition by interacting with residues outside Pro-Asn-Ala-Ile-Gly motif","volume":"38","author":"Yooin","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bcp.2024.116587_b0280","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/sctm.20-0293","article-title":"Systemic DKK1 neutralization enhances human adipose-derived stem cell mediated bone repair","volume":"10","author":"Negri","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.bcp.2024.116587_b0285","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/jbmr.472","article-title":"Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury","volume":"26","author":"Li","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.bcp.2024.116587_b0290","doi-asserted-by":"crossref","first-page":"pe22","DOI":"10.1126\/scisignal.2003028","article-title":"The structural basis of DKK-mediated inhibition of Wnt\/LRP signaling","volume":"5","author":"Bao","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bcp.2024.116587_b0295","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1021\/jm9014197","article-title":"(1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless \u03b2-catenin agonist that increases bone formation rate","volume":"52","author":"Pelletier","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116587_b0300","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bmcl.2009.10.093","article-title":"Hit to lead studies on (hetero)arylpyrimidines\u2014agonists of the canonical Wnt-\u03b2-catenin cellular messaging system","volume":"20","author":"Gilbert","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2024.116587_b0305","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1210\/me.2003-0498","article-title":"The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice","volume":"18","author":"Bodine","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2024.116587_b0310","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bone.2009.02.013","article-title":"A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation","volume":"44","author":"Bodine","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2024.116587_b0315","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1021\/jm801069w","article-title":"Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors","volume":"51","author":"Gopalsamy","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116587_b0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/jm801144h","article-title":"Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides","volume":"52","author":"Moore","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116587_b0325","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bmc.2009.11.002","article-title":"Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II","volume":"18","author":"Moore","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116587_b0330","doi-asserted-by":"crossref","first-page":"375","DOI":"10.15252\/emmm.201505714","article-title":"Small molecule inhibitors of the Dishevelled- -CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy","volume":"8","author":"Kim","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2024.116587_b0335","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsmedchemlett.8b00191","article-title":"Selective irreversible inhibitors of the wnt-deacylating enzyme NOTUM developed by activity-based protein profiling","volume":"9","author":"Suciu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2024.116587_b0340","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.devcel.2015.02.014","article-title":"Notum is required for neural and head induction via wnt deacylation, oxidation, and inactivation","volume":"32","author":"Zhang","year":"2015","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bcp.2024.116587_b0345","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1021\/jm9018756","article-title":"Emerging targets in osteoporosis disease modification","volume":"53","author":"Allen","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116587_b0350","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.bmcl.2016.02.021","article-title":"Stimulation of cortical bone formation with thienopyrimidine based inhibitors of Notum Pectinacetylesterase","volume":"26","author":"Tarver","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2024.116587_b0355","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41413-018-0038-3","article-title":"NOTUM inhibition increases endocortical bone formation and bone strength","volume":"7","author":"Brommage","year":"2019","journal-title":"Bone Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224005872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224005872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:06:12Z","timestamp":1733130372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224005872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":71,"alternative-id":["S0006295224005872"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116587","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of Wnt antagonists by small molecules for treatment of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116587"}}